Home › Heart Failure › Kansas › Overland Park
Heart Failure clinical trials in Overland Park, KS
4 studies for Heart Failure are looking for participants at sites in and around Overland Park (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
RecruitingPhase 3
- AHMG Cardiology and Surgery, Overland Park
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
RecruitingPhase 3
- Johnson County Clintrials, Lenexa · 4 mi away
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
RecruitingPhase 3
- Research Site, Lenexa · 4 mi away
Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator
RecruitingPhase 4
- AdventHealth Shawnee Mission, Shawnee Mission · 3 mi away
About Heart Failure
Heart failure, or congestive heart failure (CHF), means the heart can't pump enough blood. Learn about the signs, symptoms, and causes.
More about Heart Failure on MedlinePlus
Heart Failure trials in other cities
- New York City, NY51 studies
- Boston, MA46 studies
- Dallas, TX42 studies
- Houston, TX35 studies
- Cleveland, OH31 studies
- Philadelphia, PA31 studies
- San Francisco, CA29 studies
- Chicago, IL28 studies
- Durham, NC25 studies
- Kansas City, MO25 studies
- St. Louis, MO24 studies
- Indianapolis, IN24 studies
Other studies in Overland Park
- Non-Small Cell Lung Cancer16 studies
- Acute Myeloid Leukemia12 studies
- Lung Cancer11 studies
- Breast Cancer10 studies
- Obesity8 studies
- Overweight7 studies
- Colorectal Cancer7 studies
- Ovarian Cancer6 studies
- Prostate Cancer6 studies
- Melanoma6 studies
- Pancreatic Cancer5 studies
- Metastatic Cancer5 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.